X4药品公司筹集了1.553亿美元的库存资金,用于治疗稀有血病。 X4 Pharmaceuticals raised $155.3 million in a stock offering to fund rare blood disease treatments.

X4制药公司于2025年10月27日关闭了公开销售,通过销售5 280万股,每股290美元,筹集了1.553亿美元的总收益,同时承保人充分行使了购买另外698万股的选择权。 X4 Pharmaceuticals closed a public offering on October 27, 2025, raising $155.3 million in gross proceeds by selling 52.8 million shares at $2.90 each, with underwriters fully exercising their option to buy an additional 6.98 million shares. 某些投资者收到预先筹资的700 000份股票授权书,每份为2.899美元,可行使,每份为0.001美元。 Certain investors received pre-funded warrants for 700,000 shares at $2.899 each, exercisable at $0.001 per share. 该公司将Nasdaq作为XFOR进行交易,计划利用这些资金用于研究、临床发展和罕见血病治疗的商业化。 The company, trading on Nasdaq as XFOR, plans to use the funds for research, clinical development, and commercialization of therapies for rare hematology diseases.